Amgen

arGEN-X appoints David Lacey to supervisory board

Friday, October 26, 2012 11:12 AM

arGEN-X, a biopharmaceutical company based in The Netherlands and focused on human monoclonal antibodies from its proprietary SIMPLE Antibody platform, has strengthened its supervisory board with the appointment of Dr. David L. Lacey.

More... »

Cytos Biotechnology appoints Itin as CEO

Friday, October 12, 2012 02:29 PM

Cytos Biotechnology, a Swiss biotech company focused on the development of CYT003 in allergic asthma, has appointed Dr. Christian Itin as chief executive officer. The board of directors will propose to the company's shareholders that Itin be elected as member of the board, and it is intended that he will become chairman.

More... »

Spectrum appoints Amgen vet Ken Keller as COO

Thursday, September 13, 2012 08:00 AM

Spectrum Pharmaceuticals, a biotechnology company focused on hematology and oncology, has appointed Ken Keller as executive vice president and COO. Keller will have global responsibility for leading commercial operations, medical and clinical development and pharmaceutical operations.

More... »

Y-Prime names Greef as senior business analyst

Thursday, August 30, 2012 02:53 PM

Y-Prime Technologies, an Malvern, Penn.-based eClinical products and life sciences consulting services company, has expanded its international operations in Europe and has named Jeanette Anne Greef as senior business analyst in the U.K. office.

More... »

Genentech and Novartis rank as image leaders among oncologists, hematologists

Wednesday, July 25, 2012 09:59 AM

Genentech and Novartis have the best image among oncologists and hematologists, according to Market Strategies International, a market research consultancy that recently completed its 2012 Oncology Image Study.

More... »

Cell Medica secures $26.5M to establish U.S. operations and fund cell therapy development

Monday, July 23, 2012 03:04 PM

Cell Medica, a London-based cell therapeutics company, has secured a $26.5 million equity investment to launch new operations in Texas focusing on cancer immunotherapy and to continue development of its immune reconstitution cell therapies in Europe.

More... »

Amgen completes acquisition of KAI Pharmaceuticals

Friday, July 6, 2012 02:13 PM

Thousand Oaks, Calif.-based Amgen has completed the acquisition of KAI Pharmaceuticals, a privately held company based in South San Francisco.

More... »

Amgen, actress Maura Tierney launch ‘Chemotherapy: Myths or Facts’ campaign

Monday, June 25, 2012 03:30 PM

Amgen, a biotech based in Thousand Oaks, Calif., has launched Chemotherapy: Myths or Facts, an awareness campaign for cancer patients and their caregivers featuring Emmy-nominated actress and breast cancer survivor Maura Tierney.

More... »

West Pharmaceutical signs tech agreement with Amgen

Thursday, June 21, 2012 02:42 PM

West Pharmaceutical Services, a global manufacturer of components and systems for injectable drug delivery, has signed an agreement with Amgen, an independent biotech based in Thousand Oaks, Calif., to evaluate Daikyo Crystal Zenith technologies for drug containment.

More... »

Amgen provides testimony to FDA stakeholder hearing on biosimilars

Monday, May 14, 2012 01:40 PM

Joseph P. Miletich, M.D., Ph.D., senior vice president of R&D at Amgen, submitted testimony to the FDA stakeholder hearing on biosimilars, urging members of the FDA panel charged with implementing a pathway for biosimilars to establish approval standards that advance patient safety and promote confidence in biosimilars marketed in the U.S.

More... »